Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Achilles Therapeutics Plc (ACHL)

Achilles Therapeutics Plc (ACHL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Pathways to Progress: How Orphan Drug Designation Sparks Biotech Transformation

NetworkNewsWire Editorial Coverage : More than 30 million people in the United States suffer with a rare disease; most of them are receiving no current treatment. Supporting the development and evaluation...

GNPX : 0.3498 (-0.03%)
RHHBY : 38.2700 (+0.74%)
JAZZ : 107.62 (-0.83%)
ALXO : 1.6500 (+3.77%)
ACHL : 1.0200 (+0.99%)
Pathways to Progress: How Orphan Drug Designation Sparks Biotech Transformation

NetworkNewsWire Editorial Coverage : More than 30 million people in the United States suffer with a rare disease; most of them are receiving no current treatment. Supporting the development and evaluation...

GNPX : 0.3498 (-0.03%)
RHHBY : 38.2700 (+0.74%)
JAZZ : 107.62 (-0.83%)
ALXO : 1.6500 (+3.77%)
ACHL : 1.0200 (+0.99%)
Pathways to Progress: How Orphan Drug Designation Sparks Biotech Transformation

EQNX::TICKER_START (NASDAQ:GNPX),(OTCQX:RHHBY),(NASDAQ:JAZZ),(NASDAQ:ALXO),(NASDAQ:ACHL) EQNX::TICKER_END

GNPX : 0.3498 (-0.03%)
RHHBY : 38.2700 (+0.74%)
JAZZ : 107.62 (-0.83%)
ALXO : 1.6500 (+3.77%)
ACHL : 1.0200 (+0.99%)
Pathways to Progress: How Orphan Drug Designation Sparks Biotech Transformation

/PRNewswire/ -- More than 30 million people in the United States suffer with a rare disease; most of them are receiving no current treatment. Supporting the...

RHHBY : 38.2700 (+0.74%)
GNPX : 0.3498 (-0.03%)
JAZZ : 107.62 (-0.83%)
ALXO : 1.6500 (+3.77%)
ACHL : 1.0200 (+0.99%)
Achilles Therapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights

- Additional clinical data from the ongoing Phase I/IIa trials in advanced NSCLC (CHIRON) and melanoma (THETIS) expected to be available in Q4 2022 - -...

ACHL : 1.0200 (+0.99%)
Achilles Therapeutics to lead Horizon Europe-Funded Consortium to Advance Personalized Cell Therapy Manufacturing

€4 million ($4.2 million) research and innovation award for consortium to develop first-in-class smart bioprocessing manufacturing platform...

ACHL : 1.0200 (+0.99%)
Achilles Therapeutics Appoints James Taylor as Chief Business Officer and Cassian Yee, MD to Scientific Advisory Board

LONDON, June 30, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T...

ACHL : 1.0200 (+0.99%)
Achilles Therapeutics Recognized with the 2022 PING Innovation Award

LONDON, June 21, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T...

ACHL : 1.0200 (+0.99%)
Achilles Therapeutics Reports First Quarter 2022 Financial Results and Recent Business Highlights

- Dosed first patient with higher-dose (Process 2) cNeT for advanced NSCLC (CHIRON) and initiated enrollment of cNeT + PD-1 inhibitor combination (THETIS...

ACHL : 1.0200 (+0.99%)
Achilles Therapeutics Doses First Patient with Higher-dose cNeT in Phase I/IIa CHIRON Trial in Advanced NSCLC and Initiates Enrollment in Cohort B of the THETIS Trial (cNeT + PD-1 checkpoint inhibitor) in Metastatic Malignant Melanoma

- THETIS Cohort B enrollment follows positive Independent Data Safety Monitoring Committee review - - Monotherapy data from higher-dose cohorts in both...

ACHL : 1.0200 (+0.99%)

Barchart Exclusives

S&P Futures Tick Lower Ahead of FOMC Meeting Minutes and More Fed Speak
December S&P 500 E-Mini futures (ESZ24) are trending down -0.12% this morning as market participants awaited the Federal Reserve’s September meeting minutes and remarks from Fed officials. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar